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Abstract: The p53 protein is a transcription factor that regulates multiple cellular processes in human and other high eu-
karyotes including cell proliferation, differentiation, cell cycle, and metabolism. The central roles played by p53 in tumor 
development have drawn extensive studies on p53 activation and inactivation. The regulation of p53 and its pathway, as 
well as its transactivational targets is of prime importance in the understanding of tumorigenesis. Recently, microRNAs 
(miRNAs) have been reported to be directly transactivated by p53. Equally, p53 and components of its pathway have been 
shown to be targeted by miRNA thereby affecting p53 activities. In this review, we focus our discussion on the biological 
and pathological roles of miRNAs in the p53 pathway. 
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INTRODUCTION 
  p53, also known as protein 53 or tumor protein p53, is a 
transcription factor that regulates multiple cellular processes 
in human and other high eukaryotes. In human, the TP53 
gene encoding the p53 protein is mutated in ~50% of all hu-
man cancers [1, 2]. p53 is activated in response to a myriad 
of stressors such as DNA-damaging agents, radiation, oxida-
tive stress, and proto-oncogenes [3]. These events usually 
culminate in activation of ATM kinase which in turn leads to 
phosphorylation of p53. Activated p53 induces cell cycle 
arrest, or promotes apoptosis depending on the cellular con-
text and extent of DNA damage. The cellular effects of p53 
are through its ability to transativate genes that affect cellular 
processes such as p21 (G1 arrest), 14-3-3 (G2 arrest) and 
PUMA (apoptosis) [4-6]. Trans-repressor activities of p53 
have also been reported, with p53 down-regulating genes 
such as the p53-mediated loss of cyclin-dependent kinase 
(CDK4) and cyclin E2 which both contribute to cell cycle 
arrest [7]. Recently p53’s ability to regulate expression of 
microRNAs (miRNAs) and its expression being regulated by 
miRNAs brings to light a novel class of genes that are regu-
lated by p53. Components of the p53 pathway have also 
been reported to be targeted by miRNAs. 
  The first known miRNA, lin-4, was discovered in 1993 
by Victor Ambros and colleagues through their study of the 
heterochromic gene lin-14 in worms. However, it was not 
until the turn of the millennium that work on miRNAs began 
in earnest, aiming at elucidating their roles in regulating pro-
tein expression. miRNAs constitute an abundant family of 
endogenously expressed 20-25 nucleotides RNAs that can 
base-pair to target messenger RNA (mRNA), inhibiting their  
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translation. miRNA-encoded genes are transcribed by RNA 
polymerase II or III to yield primary transcripts (pri-
miRNA). Pri-miRNAs are processed in the nucleus by the 
nuclear RNase III enzyme, Drosha, to stem-loop-structured 
miRNA precursor molecules (pre-miRNA). Pre-miRNA are 
transported to the cytoplasm where they are processed fur-
ther by another RNase III enzyme, Dicer, which cleaves off 
the double-stranded (ds) portion of the hairpin and generates 
a short-lived dsRNA of about 20-25 nucleotides in length. 
The resulting duplex is eventually unwound and one of the 
strands gives rise to the mature miRNA which is incorpo-
rated into the miRNA-protein complex RISC. The miRNA 
direct the RISC complex to a target mRNA 3’-UTR leading 
to either inhibition of translation or degradation of the target 
mRNA [8, 9]. It is widely believed that perfect complemen-
tarity between the miRNA and mRNA leads to mRNA deg-
radation, while partial complementarity favors translational 
repression. Moreover, miRNA nucleotide 2-9 at the 5’-end, 
christen ‘seed’ sequence, is important for targeting [9]. 
Complementarity between the miRNA ‘seed’ and the target 
mRNA is required for down-regulation of the mRNA. 
  The facts that miRNAs can target various transcripts, 
miRNAs are implicated in diverse processes including cellu-
lar differentiation, apoptosis, metabolism and cell prolifera-
tion [10]. Research over the last decade has led to the reali-
zation that certain miRNAs can be classified as oncogenes or 
tumor suppressors [11, 12]. In this review we focus on miR-
NAs that have been implicated to function in the p53 path-
way. 
miR-34 Family and Apoptosis 
  In mammals, the miR-34 family members are made up of 
three miRNAs encoded by two different genes: miR-34b/c 
(who share a common primary transcript) and miR-34a (en-
coded on its own. Recent data have shown that genes coding 
for the miR-34 family are direct transactivational targets of 
p53 and their over-expression results in the induction of The p53 Pathway Encounters the MicroRNA World  Current Genomics, 2009, Vol. 10, No. 3    195 
apoptosis, cell cycle arrest and senescence [13-16] (Fig. 1). 
Bommer  et al. [17] showed that miR-34 family members 
may be tissue specific with miR-34a being expressed at 
higher level than miR-34b/c with the exception of the lungs. 
Genome-wide analysis of miRNA expression revealed that 
miR-34a is most induced following p53 activation [13, 14, 
17]. 
  A direct molecular explanation of how miR-34 interferes 
in the p53 pathway and apoptosis is highlighted in the result 
published by Lowenstein and colleagues [18]. Their results 
showed that miR-34a inhibits the Silent Information Regula-
tor 1 (SIRT1) expression (Table 1), which in turn resulted in 
increased acethylation of p53 and expression of p21 and 
Puma. SIRT1 is a NAD-dependent de-acetylase that regu-
lates apoptosis in response to oxidative and genotoxic stress 
[19]. Recent data suggest that SIRT1 may function as an 
oncogene and plays a role in tumorigenesis [20] by deacti-
vating p53 through de-acetylation [21]. Lowenstein and col-
leagues went on to show that SIRT1 led to apoptosis in wild-
type p53 human colon cancer cells but not in human colon 
cancer lacking p53. This indicates a positive feedback loop 
exist between p53 and miR-34a through an SIRT1-p53 path- 
way. 
 Xu  et al. [30] used a different approach to show that 
miR-34a plays a central role in the p53 pathway. They 
showed that in p53-mutant gastric cancer cells, restoration of 
miR-34a resulted in inhibition of tumorisphere formation 
and growth. They further demonstrated that the mechanism 
of miR-34a mediated suppression of self-renewal of gastric 
cancer cells was related to the modulation of down-stream 
target of Bcl-2, Notch and HMGA2. This suggests that miR-
34a could partially replace p53 in inducing apoptosis or se-
nescence. Taken together, these data indicate that p53 di-
rectly activates the expression of miR-34 genes, which play 
an important role in p53-mediated apoptotic pathway. 
miR-29 Family Regulate p53 Activity 
 p85 protein is the regulatory subunit of phosphatidyli-
nositol-3 kinase (PI3K) and plays a major role in maintain-
ing the balance of cellular survival and apoptosis. p85 binds 
to PI3K catalytic subunit p110 and regulates its physiologi-
cal activity [23]. Park et al. [24] showed that p85 has two 
miR-29 binding sites in it 3’-UTR region. Also, they showed 
that miR-29 targets CDC42 3’-UTR. CDC42 protein is a 
member of the Rho family of GTPasas. It regulates cell mor-
phology, cell migration and cell cycle progression [25]. Data 
gathered by Park et al. [24] showed that miR-29 down-
regulates CDC42 and p85, which in turn lead to activation 
of p53. Over-expression of miR-29 in Hela cells resulted in 
up-regulation of p53 as well as increased p53-mediated 
apoptosis. However, over-expression of miR-29 alone, un-
like miR-34a, could not lead to apoptosis, but as miR-29 
functioning in apoptosis required wild type p53 as apoptosis 
was not observed when miR-29 was over-expressed in p53-
null nor p53 mutant cells. This finding further provides 
added evidence on the role of miRNA in the p53 pathway 
and tumorigenesis. Paradoxically, miR-29 acted in a fashion 
different from miR-34 since it is an apoptotic inducer only in 
the presence of wild type p53 gene. 
miR-192 and miR-215 Induces p53-Mediated Cell Cycle 
Arrest 
  One of the physiological roles of p53 is cell cycle arrest, 
mediated as a result of p53 transcriptional activation of ei-
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ther p21 (G1 arrest) and/or 14-3-3 (G2 arrest). In a recent 
paper published by Dobbelstein and colleagues [26] p53 was 
shown to induce, together with miR-34a, three additional 
miRNAs: miR-192, miR-194, and miR-215. These miRNAs 
increase p53 and p21 protein levels, suppress colony forma-
tion, and promote cell cycle arrest. Interestingly, the effect of 
these miRNAs on colony formation was only partially p53-
dependent. Thus, miR-192, miR-194 and miR-215 are re-
garded as an amplifier to p53 and p53-dependent mediators 
of cell cycle arrest. However, it is worth noting that in-
creased expression of these three miRNAs was not solely 
p53-dependent, since p53 is a ubiquitously expressed protein 
whereas these miRNAs are specifically found in the liver 
and colon [27]. Therefore, factors other than p53 are respon-
sible for the increase in miR-192 and miR-215 expression 
level. Chau and colleagues [28] showed that genotoxic stress 
could lead to up-regulation of miR-192 and miR-215, which 
in turn lead to a gene expression signature that is highly en-
riched for regulators of cell cycle. These results imply that 
miR-192 and miR-215 work in synergy with the p53 path-
way in regulating cell cycle arrest and thus they are critical 
to tumor formation. 
miR-372 and miR-373 can Substitute for Loss of Wild 
Type (WT) p53 
  Escaping from oncogene-induced senescence is a pre-
requisite for cell transformation. Under oncogenic stress, 
cells usually arrest excessive cell proliferation by activating 
the p53 pathway. Agami and colleagues [29] showed that 
over-expression of the miR-371 cluster was sufficient to 
overcome cell proliferative arrest following RAS
V12 intro-
duction. Two miRNAs in this cluster, miR-372 and miR-373 
induced cell transformation with oncogenic RAS and WT 
p53. Their results suggest that miR-272 and miR-373 may 
participate in the tumorigenesis of tumors with WT p53 and 
are sensitive to DNA damaging treatment. The Large Tumor 
suppressor Homolog 2 (LATS2) is a serine kinase whose 
deletion in flies and mice accelerates cellular proliferation 
and tumorigenic development [30, 31]. Its over-expression 
was shown to inhibit cyclin E/CDK2 activity and RAS me-
diated transformation [32]. It was reported that LATS2 
down-regulation stimulates reduplication (same as cyclin E 
over-expression) [33]. Agami and colleagues were able to 
show that miR-372 and miR-373 neutralize p53-mediated 
CDK inhibition, possibly through direct inhibition of the 
expression of the tumor-suppressor LATS2. 
Other miRNAs that Regulate p53 Activity 
  The miR-17-92 cluster has been shown to result in down-
regulation of Bim [34]. Sawada laboratory [35] showed that 
overexpression of miR-17-92 resulted in upregulation of c-
Myc, decreased expression of p21 that was independent of 
p53 expression. This result showed that certain miRNA 
could affect important components of the p53 pathway such 
as Bim and subsequently result in apoptosis independently of 
p53. 
 Kosik  et al. [36] demonstrated miR-21 directly targets 
two components in the p53 network. The first one is 
HNRPK, which can stabilize p53 protein level by interfering 
with MDM2 and/or act as p53 transcriptional co-activation; 
and the second is TAp63, which is an isoform of p63, a ho-
molog of p53, and possesses a transactivation domain at the 
N terminus and are able to transactivate a set of genes, in-
cluding some targets downstream of p53. These results sug-
gest that miR-21 is an oncogene as it functions against p53 
or its target gene activity. 
 
Table  1.    miRNAs Function in the p53 Pathway and their 
Target Genes 
miRNAs Targets  Ref. 
Cyclin E2 (CCNE2) 
Cyclin dependent 
kinase 4 (CDK4) 
Hepatocyte growth factor receptor (MET) 
[14] 
Silent Information Regulator 1 (SIRT1)  [18] 
miR-34 
Bcl-2, Notch and HMGA2 downstream target  [22] 
miR-29 
p85a 
CDC42 
[24] 
miR-192/ 
194/215 
Direct target – unknown 
Indirect target – up-regulate p53 and p53 
[26] 
miR-372/373  Large Tumor Suppressor Homolog 2 (LATS2)  [29] 
miR-17-92 
Direct target – Bim 
Indirect target – p21 (up), c-Myc (down) 
[35] 
miR-21 
p63 
HNRPK 
[26] 
 
CONCLUSION 
  Recent progresses on miRNAs in the p53 pathway have 
demonstrated that the p53 tumor suppressor network cross-
talks with the miRNA regulation system. Prominent among 
them is the finding that miR-34 family is a direct transactiva-
tional target of p53 and it induces apoptosis, cell cycle arrest 
and senescence [12-15]. The miR-34 story set the precedence 
and a number of papers have now been published showing 
that other miRNAs interfere the p53 pathway, in a p53-
independent manner (miR-34), partial p53-dependent man-
ner (miR-192, miR-194, miR-215, and miR-21) or a p53-
dependent manner (miR-29). Furthermore, miRNAs is im-
plicated in every aspect of cellular outcome of p53 activa-
tion: apoptosis (miR-34 and miR-29), cell cycle arrest (miR-
192, miR-194, and miR-215), and senescence (miR-34). 
These exciting results prompt us to contemplate the use of 
miRNAs in therapeutics against cancer, yet much work is 
needed to further elucidate the intricacy of the interaction 
between miRNAs and the p53 pathway. 
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